- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03158012
Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients
October 18, 2019 updated by: Richard Gallo, University of California, San Diego
Unlike healthy control skin, the skin of patients with atopic dermatitis (AD) is frequently colonized by Staphylococcus aureus (S. aureus), putting these patients at increased risk of S. aureus skin infections.
In addition, research in the investigator's lab has shown that these patients have fewer protective antimicrobial Staphylococcal species such as Staphylococcal epidermidis (S. epidermidis) that are known to produce antimicrobial peptides that play a role in protecting the skin from invading pathogens.
In this study, the investigator will attempt to decrease S. aureus colonization and increase colonization of protective Staph species in AD patients.
First the investigator will capture the bacteria on subjects' skin.
Next the investigator will selectively grow the subject's antimicrobial Staphylococcal colonies and place them into a base moisturizer.
The moisturizer plus bacteria will be applied to one of the subject's arms for one week.
Some subjects will receive placebo, which is the moisturizer alone (without bacteria).
The investigator will then swab the arms at specified time points during and after the one week application in order to determine whether the S. aureus abundance was affected by the application of the transplanted bacteria.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92122
- University of California San Diego Dermatology Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects who are not pregnant or lactating. Female subjects of child-bearing potential must have a negative urine pregnancy test on the day of the screening visit in order to be eligible for the study.
- 18-60 years of age
- Diagnosis of atopic dermatitis for at least 6 months using the Hanifin and Rajka Diagnostic Criteria for atopic dermatitis
- Presence of lesional atopic dermatitis skin in both antecubital fossae
- Positive S. aureus colonization based on results of a skin culture taken from one of their AD-affected antecubital fossae
- Positive for antimicrobial CoNS species from non-lesional AD skin
Exclusion Criteria:
- Use of any topical AD treatments (including topical steroids, topical calcineurin inhibitors) to either arm within one week of the Treatment visit
- Use of any antihistamines 7 days within one week of the Treatment visit
- Use of any oral/systemic AD therapies (steroids) within 28 days of the Treatment visit
- Severe AD that would worsen significantly from holding a participant's usual topical/oral AD medications for the time periods required in the inclusion/exclusion criteria (one week prior to the Treatment visit for topical medications and antihistamines and 28 days prior to Treatment visits for oral medications)
- Subjects who have taken a bleach bath within a week prior to the Treatment visit, or who take bleach baths during the study
- Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study
- Subjects with Netherton's syndrome or other genodermatoses that result in a defective epidermal barrier
- Any subject who is immunocompromised (e.g. provides researchers with a history lymphoma, HIV/AIDS, Wiskott-Aldrich Syndrome) or has a history of malignant disease (with the exception of non-melanomatous skin cancer). This information will be gathered verbally from the patient while taking a medical history from the patient, and will not involve further testing such as an HIV test.
- Subjects with a history of psychiatric disease or history of alcohol or drug abuse that would interfere with the ability to comply with the study protocol
- Active bacterial, viral or fungal skin infections
- Any noticeable breaks or cracks in the skin on either arm, including severely excoriated skin or skin with open or weeping wounds suggestive of an active infection or increased susceptibility to infection.
- Ongoing participation in another investigational trial
- Use of any oral or topical antibiotic for up to four weeks prior to the Treatment visit
- Use of any systemic immunosuppressive therapy (e.g. CsA, MTX, etc.) within four weeks of the Treatment visit.
- Sensitivity to or difficulty tolerating Dove fragrance-free bar soap or Cetaphil lotion
- Subjects with prosthetic heart valves, pacemakers, intravascular catheters, or other foreign or prosthetic devices.
- Allergy or intolerability to soy or macadamia nuts.
- Participant who has a condition or is in a situation that, in the investigator's opinion, may put the patient at significant risk, or may significantly interfere with the patient's participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo treatment
|
Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
|
Active Comparator: Active treatment
|
Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative Abundance of Staphylococcus Aureus Compared to Baseline
Time Frame: 24 Hours
|
Relative abundance of S. aureus 24 hours after initial treatment application (baseline).
|
24 Hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Richard Gallo, MD, PhD, UCSD School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2016
Primary Completion (Actual)
December 1, 2017
Study Completion (Actual)
August 1, 2018
Study Registration Dates
First Submitted
May 9, 2017
First Submitted That Met QC Criteria
May 16, 2017
First Posted (Actual)
May 17, 2017
Study Record Updates
Last Update Posted (Actual)
November 7, 2019
Last Update Submitted That Met QC Criteria
October 18, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCSD 131244.4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis Eczema
-
University of California, DavisCompletedAtopic Dermatitis | Hand Eczema | Atopic Eczema | Infantile EczemaUnited States
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
Kari Nadeau, MD, PhDUniversity of Chicago; Stanford University; Children's Hospital Medical Center... and other collaboratorsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Eczema, InfantileUnited States, United Kingdom
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Groningen Research Institute for Asthma and COPDNumico Research Wageningen, the NetherlandsCompletedAtopic Dermatitis | Atopic Eczema | Infantile EczemaNetherlands
-
Petra LarmoCliniscan LtdTerminated
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
University College CorkCompletedEczema | Food Allergy | Eczema, Infantile | Eczema Atopic DermatitisIreland
Clinical Trials on Autologous Microbial Transplant
-
VA Office of Research and DevelopmentCompleted
-
University GhentCompletedHeavy, Bad Body Odour From Armpit | Heavy, Bad Body Odour From FootBelgium
-
University GhentUniversity Hospital, GhentCompleted
-
Beth Israel Deaconess Medical CenterBrigham and Women's Hospital; The Broad FoundationCompletedCrohn's DiseaseUnited States
-
Griffin HospitalYale-Griffin Prevention Research Center; Multiple Sclerosis Treatment Center...Active, not recruitingMultiple SclerosisUnited States
-
Helsinki University Central HospitalUniversity of HelsinkiActive, not recruitingFecal Microbiota Transplantation | Cesarean Section, Affecting Fetus or Newborn | Intestinal MicrobiomeFinland
-
Lawson Health Research InstituteSt. Joseph's Health Care LondonNot yet recruitingArthritis | Arthritis, Rheumatoid | Fecal Microbiota Transplantation
-
MemorialCare Health SystemMemorial Medical Center FoundationCompletedClostridium Difficile ColitisUnited States
-
Mayo ClinicCompleted
-
Joshua SternAlbert Einstein College of Medicine; University of Minnesota; Litholink CorporationNot yet recruiting